- Home
- PAMT vs FENC Comparison
PAMT vs FENC Comparison
Compare PAMT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$10.65
HOLD
Current Price
$7.51
Company Overview
Basic Information| Metric | PAMT | FENC |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.0M | 263.3M |
| IPO Year | 1985 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PAMT | FENC |
|---|---|---|
| Price | $10.65 | $7.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $13.00 | ★ $15.00 |
| AVG Volume (30 Days) | 23.9K | ★ 116.0K |
| Earning Date | 02-06-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $623,270,000.00 | $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.19 | $70.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.90 | $4.68 |
| 52 Week High | $17.29 | $9.92 |
Technical Indicators
Market Signals| Indicator | PAMT | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 47.61 |
| Support Level | $10.06 | $7.37 |
| Resistance Level | $11.15 | $7.95 |
| Average True Range (ATR) | 0.61 | 0.26 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 26.12 | 35.00 |
Price Performance
Historical Comparison PAMT
FENC
About PAMT PAMT CORP
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.